Quantum Computing Inc. and INmune Bio Partner on Alzheimer's Research

The partnership integrates quantum computing with existing artificial intelligence and data analytics frameworks to process the extensive clinical datasets held by INmune Bio. By leveraging the Dirac-3S system, the companies aim to uncover therapeutic potential that traditional computing methods may overlook. The agreement is structured to allow for expansion as INmune’s clinical development programs evolve.

Chief Executive Yuping Huang noted that the collaboration addresses the complex biological data inherent in drug development, positioning the project as a test case for quantum utility in biotechnology. For QCi, the deal represents a strategic entry into a new market, focusing on enhancing decision-making capabilities for researchers navigating future treatment pathways.